KBP-5074 for CV disease/Hypertension in CKD patients – Initiated global Phase 2b in Q1 2018
KBP-7072 for multiple drug resistant infections – Finish Phase 1 – Ready for global Phase 2
KBP-7026 novel CRTH2 receptor antagonist targeting asthma/COPD – IND Approved & Ready for Phase 1
Johan M.(Thijs) Spoor, MBA, CEO
Nick Hart, CFO
Fred Yang, PhD, CDO
Michael Miernicki, PhD, VP
Vince Benn, PhD/MBA, VP
Jay (Xu-Jie) Zhang, PhD, VP
Jerry Zhong, PhD, MBA, PMP, VP
James McCabe, MD, VP
Pengfei (Murphy) Guo, PhD, AVP
A. Sophia Hurtado, RN, Senior Director
SCIENTIFIC ADVISORY BOARD 5074
George Bakris, MD (US)
John McMurray, MD (UK)
Bertram Pitt, MD (US)
Faiez Zannad, MD (FR)
Frédéric Jaisser, MD, PhD
Clare Kahn, PhD
SCIENTIFIC ADVISORY BOARD 7072
Ricard Wunderink, MD (US)
KBP BioSciences to present at Biotech Showcase 2020
KBP BioSciences signs memorandum of understanding with Bullforg AI
KBP Biosciences Co., Ltd. attended the 2017 China BioMed Innovation and Investment Conference.
Positive FDA Type B Meeting on KBP-5074
KBP-7072 obtained QIDP and Fast Track Designations
Jennifer Miao jennifer.miao@kbpbiosciences.com
116 Village Blvd., Suite 210 Princeton, NJ 08540
Phone: (609) 531-0889 (Office) / (732) 429-0898 (Cell)
